AI English summary of an SEC filing — figures as filed
Elevance Health ELVElevance Health said operating revenue for Q3 2025 rose 12.0% from the prior year to $50.1 billion. The company also reported diluted EPS of $5.32 and adjusted diluted EPS of $6.03.
Key points
AI summaryElevance Health said operating revenue for Q3 2025 rose 12.0% from the prior year to $50.1 billion. The company also reported diluted EPS of $5.32 and adjusted diluted EPS of $6.03.
Elevance Health said its benefit expense ratio for Q3 was 91.3%, up 180 basis points from a year earlier, and its operating margin was 2.6% compared with 3.1% a year earlier. It described the cost trend in its Medicare business, which reflects the seasonality of Part D benefits.
The company reaffirmed its outlook for a benefit expense ratio of approximately 90.0% and adjusted diluted EPS of approximately $30.00 for fiscal 2025, Elevance Health said. It gave full-year diluted EPS of approximately $24.70.
Elevance Health said operating cash flow for the period through September 30 was $4.2 billion, down $0.9 billion from a year earlier, and that it returned $3.3 billion to shareholders. It repurchased 2.9 million shares at an average price of $875 million in Q3.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Q3 operating revenue $50.1 billion, diluted EPS $5.32
Elevance Health said operating revenue for Q3 2025 rose 12.0% from the prior year to $50.1 billion. The company also reported diluted EPS of $5.32 and adjusted diluted EPS of $6.03.
Source · Based on the filing body and exhibits
Q3 benefit expense ratio 91.3%, operating margin 2.6%
Elevance Health said its benefit expense ratio for Q3 was 91.3%, up 180 basis points from a year earlier, and its operating margin was 2.6% compared with 3.1% a year earlier. It described the cost trend in its Medicare business, which reflects the seasonality of Part D benefits.
Source · Based on the filing body and exhibits
Reaffirms full-year benefit expense ratio and adjusted EPS outlook
The company reaffirmed its outlook for a benefit expense ratio of approximately 90.0% and adjusted diluted EPS of approximately $30.00 for fiscal 2025, Elevance Health said. It gave full-year diluted EPS of approximately $24.70.
Source · Based on the filing body and exhibits
Year-to-date operating cash flow $4.2 billion, shareholder returns $3.3 billion
Elevance Health said operating cash flow for the period through September 30 was $4.2 billion, down $0.9 billion from a year earlier, and that it returned $3.3 billion to shareholders. It repurchased 2.9 million shares at an average price of $875 million in Q3.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…